SIBN
SI-BONE, Inc. Common Stock
stockNASDAQ
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 18.76 | 2026-09-28 | -3.57% | -2.094 |
| 1M | 18.50 | 2026-09-04 | -2.22% | -0.109 |
| 3M | 17.68 | 2026-07-06 | +2.32% | 0.151 |
| 6M | 13.21 | 2026-04-06 | +36.94% | 0.301 |
| 1Y | 14.49 | 2025-10-06 | +24.84% | 0.581 |
| 2Y | 14.68 | 2024-10-04 | +23.23% | — |
| 5Y | 21.32 | 2021-10-05 | -15.15% | 1.072 |
SI-BONE, Inc. Common Stock (NASDAQ:SIBN) stock price today is $18.09, and today's volume is 547,323. SIBN is down 1.738% today. The 30 day average volume is 594,503. SIBN market cap is $810.77M with 44.82M shares outstanding.